A Khavinson bioregulator (synthetic KEDP) marketed for prostate tissue — short cycles for age-related prostate function, urinary support, and BPH symptoms. Most prostate-RCT clinical evidence is for the parent extract Prostatilen / Vitaprost, not synthetic KEDP.
Prostamax (sequence Lys-Glu-Asp-Pro / KEDP, the synthetic tetrapeptide; NOT to be confused with Prostamol-UNO, a saw-palmetto extract product) is a short synthetic peptide from the Khavinson bioregulator family. It’s dosed in short cycles and is theorized to work via tissue-specific gene-expression modulation.
Important attribution caveat: the published Russian RCT clinical evidence base for “BPH symptom relief” and “chronic prostatitis benefit” (PMIDs 19432231 Vitaprost RCT, 24640697 Chitomur RCT, 34251104 Vitaprost comparative) is for the parent polypeptide complex (Prostatilen / Vitaprost — the registered Russian pharmaceutical extracted from young animal prostate) and a sister bioregulator (Chitomur, bladder-derived) — not for synthetic KEDP. Of the six PubMed-indexed papers naming “Prostamax” by trade name, only one (PMID 17152728) tested KEDP on prostate tissue (rat organotypic explant); five measure lymphocyte chromatin in elderly donors. Treat the prostate-specific clinical claim as an extrapolation from the parent extract, not a direct finding for KEDP.
Used for age-related prostate maintenance, early BPH symptoms, mild prostatitis, and as a general preventive in aging men. It is not a treatment for prostate cancer; the parent extract Prostatilen has been reported (PMID 26390619) to drive PCNA↑ and p53↓ in prostate organotypic culture, which warrants caution with active or prior prostate malignancy.
Not FDA approved. Synthetic Prostamax (KEDP) is sold in Russia as a “biologically active dietary supplement” (БАД); the parent extract Prostatilen / Vitaprost is the registered Russian pharmaceutical. Not specifically listed on the WADA prohibited list, though the S0 catch-all may apply. Available as oral capsule or injectable.
Per Khavinson's bioregulator framework, short peptides interact with tissue-relevant DNA regions. Mechanistic work documents docking and nuclear penetration; direct demonstration of synthetic KEDP modulating prostate-specific gene expression in human prostate tissue is not established. The "binds prostate-relevant DNA promoter regions" framing is mechanistic inference from the broader Khavinson literature.
Anti-inflammatory effects in prostate tissue are documented for the parent extract Prostatilen / Vitaprost (the registered Russian pharmaceutical), not for synthetic KEDP specifically. The KEDP-on-prostate inflammatory effect is extrapolation, not direct measurement.
Unlike finasteride, Prostamax does not block DHT conversion or alter androgen signaling. Different mechanism, often used alongside 5AR inhibitors or alpha-blockers for additive effect.
Research is primarily Russian cohort data in aging male populations. Western clinical replication is limited. Expect modest, accumulating effects rather than dramatic acute changes.
| Benefit | Evidence |
|---|---|
| BPH symptom relief | Parent extract Prostatilen / Vitaprost Russian RCTs (PMID 19432231 Vitaprost, PMID 34251104 Vitaprost comparative) reported IPSS reduction. Not directly demonstrated for synthetic KEDP. |
| Urinary function | Uroflow and post-void residual improvements reported for the parent extract; KEDP-specific data is extrapolation. |
| Prostatitis | Russian clinical adjunct use in chronic non-bacterial prostatitis (parent extract). KEDP-specific evidence: one rat organotypic explant study (PMID 17152728). |
| Age-related maintenance | Used preventively in aging men in Russian community/clinical practice before significant BPH develops. No Western RCT. |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeGet a baseline PSA, DRE, and IPSS before starting. Recheck annually. Any changes in urinary symptoms, bleeding, or new nocturia should prompt evaluation — don’t assume it’s "the peptide working."
Most commonly supplied as oral capsules — no reconstitution needed. For injectable powder, follow the same protocol as Cartalax (see Cartalax guide) with 20 mg vial + 2 mL BAC water = 10 mg/mL.
Pre-filled with a typical Prostamax setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Clean safety profile in reported Russian clinical use. Rare side effects, no hormonal alteration.
Looking for Prostamax? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeProstamax (sequence Lys-Glu-Asp-Pro / KEDP, the synthetic tetrapeptide; not to be confused with Prostamol-UNO, a saw-palmetto extract product) is a short synthetic peptide from the Khavinson bioregulator family. It is dosed in short cycles and is theorized to work via tissue-specific gene-expression modulation. Used for age-related prostate maintenance, early BPH symptoms, mild prostatitis, and as a general preventive in aging men. It is not a treatment for prostate cancer.
Important attribution caveat: the published Russian RCT clinical evidence base for BPH symptom relief and chronic prostatitis benefit (PMIDs 19432231 Vitaprost RCT, 24640697 Chitomur RCT, 34251104 Vitaprost comparative) is for the parent polypeptide complex (Prostatilen / Vitaprost, the registered Russian pharmaceutical extracted from young animal prostate) and a sister bioregulator (Chitomur, bladder-derived), not for synthetic KEDP. Of the six PubMed-indexed papers naming Prostamax by trade name, only one (PMID 17152728) tested KEDP on prostate tissue (rat organotypic explant); five measure lymphocyte chromatin in elderly donors. Treat the prostate-specific clinical claim as an extrapolation from the parent extract.
No. Prostamax is not FDA approved. Synthetic Prostamax (KEDP) is sold in Russia as a biologically active dietary supplement (BAD); the parent extract Prostatilen / Vitaprost is the registered Russian pharmaceutical. Not specifically listed on the WADA prohibited list, though the S0 catch-all for non-approved substances may apply. Available as oral capsule or injectable.
Standard cycle is 100 to 400 mcg/day for 10 to 20 days, run 2 to 4 cycles per year. Most common route is oral capsule, with SubQ as an alternative. Get a baseline PSA, DRE, and IPSS before starting, and recheck annually. Any changes in urinary symptoms, bleeding, or new nocturia should prompt evaluation rather than be attributed to the peptide working.
Clean safety profile in reported Russian clinical use with rare side effects: mild GI discomfort (oral) or injection site reactions (SubQ). The more serious concern is cancer-history caution: the parent extract Prostatilen has been reported (PMID 26390619) to drive PCNA up and p53 down in prostate organotypic culture, meaning proliferative-marker upregulation and tumor-suppressor downregulation in prostate tissue specifically. Personal or family history of prostate cancer, prostatic intraepithelial neoplasia (PIN), or significant PSA elevation warrants urology or oncology oversight, not just currently active disease. The argument is stronger here than for other Khavinson peptides because the target tissue itself is the at-risk tissue.
Different mechanisms. Unlike finasteride, Prostamax does not block DHT conversion or alter androgen signaling, and it is often used alongside 5-alpha-reductase inhibitors or alpha-blockers for additive effect rather than as a substitute. Saw palmetto is a separate herbal product entirely; the confusingly named Prostamol-UNO is a saw palmetto extract, not Prostamax. Prostamax has no Western RCT evidence and the KEDP-specific clinical record is one rat organotypic explant study, so it should not be treated as a substitute for evaluation of urinary or prostate symptoms by a urologist.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.